AbstractThe emergence of SARS-CoV 2 caused the COVID-19 pandemic, resulting in numerous
global infections and deaths. In particular, people with metabolic diseases
display an increased risk of severe COVID 19 and a fatal outcome. Treatment
options for severe cases are limited, and the appearance of new virus variants
complicates the development of novel therapies. To better manage viral
infections like COVID 19, new therapeutic approaches are needed. Marine sponges
offer a natural and renewable source of unique bioactive agents. These sponges
produce secondary metabolites with various effects, including anti-viral,
anti-inflammatory, and anti-tumorigenic properties. In the current study, we
investigated the effect of five different marine sponge-derived secondary
metabolites (four bromotyrosines and one sesquiterpenoid hydroquinone). Two of
these, Avarol and Acetyl-dibromoverongiaquinol reduced the expression of ACE2,
the main receptor for SARS-CoV 2, and the alternative receptor NRP1. Moreover,
these substances derived from sponges demonstrated the ability to diminish the
virus titer in SARS-CoV 2-infected cells, especially concerning the Omicron
lineage. However, the reduction was not substantial enough to expect a
significant impact on infected humans. Consequently, the investigated
sponge-derived secondary metabolites are not likely to be effective to treat
COVID 19 as a stand-alone therapy.